

BioGaia's result for second quarter to exceed market expectations

(Figures in brackets refer to the same period the previous year)

BioGaia's sales for the second quarter has been positively impacted by an increased demand mainly from the European market.

Sales for the second quarter are preliminarily estimated at SEK 288 million (203), up 42%. Operating profit for the second quarter is preliminarily estimated at SEK 101 million (69), up 46%.

BioGaia will publish the interim report for the second quarter on Friday, 22 July 2022 at 08:00 a.m., followed by a teleconference at 09:30 a.m.

Latest press releases from BioGaia:

01.07.2022 BioGaia launches probiotic product to support children's respiratory health
08.06.2022 BioGaia signs exclusive agreement in South Korea for the baby gut health range
31.05.2022 New number of shares and votes in BioGaia AB (publ)

For more information, please contact:

Alexander Kotsinas, CFO: +46 8 555 293 00

This is information that BioGaia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person, at 08:00 a.m. CEST on 14 July 2022.